TRiNDS Lands Investment

What does TRiNDS do?

TRiNDS, is a contract research organization born from the Cooperative International Neuromuscular Research Group. It stands for Therapeutic Research in Neuromuscular Disorders Solutions, which is a specialized contract research organization. They have a team clinical trial specialists who are focused on neuromuscular and rare disease. The team members have more than fifteen years of experience in drug development and pharma-sponsored clinical trials research programs. The team has success in setting up, runnning and completed key clinical trial programs. The company provides four main areas of support to biotechnology industries, pharmaceutical industries and clinical trial sites and academic investigators.

How much TRiNDS was funded?

TRiNDS raised undisclosed amount in undisclosed round on December 19, 2016 from CureDuchenne Ventures.

What is next for TRiNDS?

The company is involved in all phases of the clinical trial process and they can help guide the development of the right target and endpoint across the total disease spectrum. The funding will be used for accelerating its operations.

More about TRiNDS

This company provides specialized clinical trial support and post marketing solutions for neuromuscular, especially Duchenne, clinical research. The company provides 4 main solutions to the biotech and pharma industries as well as academic investigators and clinical centers for the clinical requirements: data management, clinical operations, study measurements and biostats. It is a specialized CRO- contract research organization for neuromuscular diseases. Members of their team, have a long term commitment for drug development and transactional research in the neuromuscular community. It is a strong management team, neuromuscular clinical trial and statistical analysis expertise providing a centralized infrastructure supportive of orphan drug development. This is important for helping to support clinical trials which will lead to approved treatment of Duchenne muscular dystrophy. The company has more than 15 years of experience coordinating neuromuscular clinical research studies.